Blog
RSS FeedPosted by Michael Wonder on 03 Oct 2023
US Judge refuses to block Medicare from negotiating drug prices
29 September 2023 - The US Government's Medicare health insurance program can begin negotiating prices for some prescription drugs this ...
Posted by Michael Wonder on 26 Sep 2023
Medicare Advantage and Medicare prescription drug programs to remain stable in 2024
26 September 2023 - Today, the Centers for Medicare & Medicaid Services announced that average premiums, benefits, and plan choices for ...
Posted by Michael Wonder on 05 Sep 2023
Novartis sues US Government over Medicare drug price regulation
1 September 2023 - Swiss drug maker Novartis on Friday said it had sued the US Government in an attempt ...
Posted by Michael Wonder on 29 Aug 2023
HHS selects the first drugs for Medicare drug price negotiation
29 August 2023 - For the first time, Medicare will be able to negotiate prices directly with drug companies, lowering ...
Posted by Michael Wonder on 28 Aug 2023
AstraZeneca sues US over Medicare drug price negotiation plans
25 August 2023 - AstraZeneca said on Friday it has sued the US Government to block parts of a program ...
Posted by Michael Wonder on 22 Aug 2023
CMS issues draft guidance on new program to allow people with Medicare to pay out of pocket prescription drug costs in monthly payments
21 August 2023 - New Medicare prescription payment plan will help people pay Medicare Part D costs over the year instead ...
Posted by Michael Wonder on 20 Aug 2023
US eyes battle with drug giants over 10 costly medications for seniors
18 August 2023 - The Biden administration is set to announce the first targets for price negotiation, part of a broader ...
Posted by Michael Wonder on 15 Aug 2023
DOJ blasts industry attempt to delay Medicare drug price negotiations
14 August 2023 - The Department of Justice has lambasted the Chamber of Commerce’s request for an injunction to block ...
Posted by Michael Wonder on 11 Aug 2023
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA mutated metastatic castration-resistant prostate cancer
11 August 2023 - Today, the FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech), ...
Posted by Michael Wonder on 31 Jul 2023
CMS releases 2024 projected Medicare Part D premium and bid information
31 July 2023 - The CMS today announced that the average total monthly premium for Medicare Part D coverage is projected ...
Posted by Michael Wonder on 29 Jul 2023
Statutory authority for Medicare coverage decisions - CMS is an independent federal agency
28 July 2023 - It is time for the public to recognize and strongly support the authority of the US Centers ...
Posted by Michael Wonder on 20 Jul 2023
Changes to CADTH’s rapid response service
20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
Posted by Michael Wonder on 14 Jul 2023
Chamber of Commerce asks judge to block Medicare drug price negotiations before October
12 July 2023 - The US Chamber of Commerce on Wednesday asked a federal judge in Ohio to block Medicare’s new ...
Posted by Michael Wonder on 14 Jul 2023
Health Canada approves Lynparza in combination with abiraterone and prednisone or prednisolone for patients with BRCA mutated metastatic castration-resistant prostate cancer
13 July 2023 - Conditional approval based on data from Phase 3 PROpel trial. ...
Posted by Michael Wonder on 09 Jul 2023
Medicare’s plan for drug-price negotiation - the importance of defining generic entry
8 July 2023 - The Inflation Reduction Act allows CMS to negotiate prices for a small number of Medicare covered ...